Holland Capital

Prolira BV is a Dutch company based in Utrecht that specializes in developing medical technology for the early detection of delirium, an acute brain failure condition. Founded in 2015, Prolira has introduced DeltaScan, an EEG-based device designed to monitor brain activity and facilitate timely treatment for patients at risk of acute encephalopathy and delirium. The DeltaScan system comprises a single-use electrode patch, known as the DeltaScan Patch, and the DeltaScan Monitor, which employs a validated proprietary algorithm to analyze EEG data. This innovative approach aims to enhance patient recovery by supporting clinicians in identifying and addressing delirium, a condition that affects approximately 20 million patients annually in hospitals across Europe and the United States, leading to significant cognitive impairment and increased healthcare costs.

Prolira BV is a Dutch company based in Utrecht that specializes in developing medical technology for the early detection of delirium, an acute brain failure condition. Founded in 2015, Prolira has introduced DeltaScan, an EEG-based device designed to monitor brain activity and facilitate timely treatment for patients at risk of acute encephalopathy and delirium. The DeltaScan system comprises a single-use electrode patch, known as the DeltaScan Patch, and the DeltaScan Monitor, which employs a validated proprietary algorithm to analyze EEG data. This innovative approach aims to enhance patient recovery by supporting clinicians in identifying and addressing delirium, a condition that affects approximately 20 million patients annually in hospitals across Europe and the United States, leading to significant cognitive impairment and increased healthcare costs.

Prolira BV is a Dutch company based in Utrecht that specializes in developing medical technology for the early detection of delirium, an acute brain failure condition. Founded in 2015, Prolira has introduced DeltaScan, an EEG-based device designed to monitor brain activity and facilitate timely treatment for patients at risk of acute encephalopathy and delirium. The DeltaScan system comprises a single-use electrode patch, known as the DeltaScan Patch, and the DeltaScan Monitor, which employs a validated proprietary algorithm to analyze EEG data. This innovative approach aims to enhance patient recovery by supporting clinicians in identifying and addressing delirium, a condition that affects approximately 20 million patients annually in hospitals across Europe and the United States, leading to significant cognitive impairment and increased healthcare costs.